Cabometyx
Payments companies reported to CMS as associated with Cabometyx. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Cabometyx, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Cabometyx
These are the largest totals companies reported as associated with Cabometyx. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Suresh Ratnam | Mcallen, TX | Medical Oncology | $161,417.15 |
| Joshua Strauss | Springfield, NJ | Hematology & Oncology | $150,988.27 |
| Munveer Bhangoo | La Jolla, CA | Medical Oncology | $150,947.49 |
| Nancy Dawson | Washington, DC | Medical Oncology | $148,237.60 |
| Sandy Liu | Encino, CA | Hematology & Oncology | $119,631.53 |
| John Sarantopoulos | San Antonio, TX | Medical Oncology | $107,470.99 |
| Jared Thorley | Salt Lake City, UT | Family | $103,053.80 |
| Stephen Saletan | New York, NY | Internal Medicine | $101,278.92 |
| Rahul Ravilla | Albany, NY | Hematology & Oncology | $97,425.24 |
| Abigail Smith | Philadelphia, PA | Adult Health (Nurse Practitioner) | $81,940.13 |
Prescribed Cabometyx?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.